Nanexa Q2 report: Advancing according to plan - ABG

Outlook focus on NEX-22 with Ph1 start in early '24e
Positive initial NEX-20 Ph1 PK reported yesterday
Live commentary today at 11:00 CET


Relevant events during the reported period

No material updates were provided in the report. During the quarter, Nanexa signed the CRO Profil for the upcoming Ph 1 study with NEX-22. During the quarter, Nanexa completed the recruitment for the NEX-20 Ph 1 study in healthy volunteers (for the multiple myeloma programme). On this, Nanexa yesterday announced initial positive PK data, where the company confirmed the controlled release of lenalidomide using its PharmaShell technology following the same pattern seen in preclinical studies. Full PK profile, safety and tolerability data will be presented in the Autumn (Nanexa will receive the data in October). Nanexa's primary focus during the quarter has been the NEX-22 project. Advancements on this project include a new preclinical study in minipigs showing long release profile of liraglutide, something already seen previously in rats. The generated preclinical data, together with more studies to come, will support the filing of a clinical trial application during the autumn. Regarding NEX-18, the company is evaluating suitable partners to study the potentially improved effects vs. current Vidaza treatment. Nanexa has engaged with a German university to move this forward. Nanexa keeps evaluating new formulations to eliminate the unwanted skin reactions for future clinical trials. Regarding partner projects, Nanexa mentioned in the report that the Novo Nordisk project is proceeding well. Moreover, Nanexa mentioned that one of the other projects (undisclosed partner) provided promising results, triggering more preclinical studies that will happen during the fall.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/nanexa/Equity-research/2023/8/nanexa---q2-report-advancing-according-to-plan/